A mechanism of action for anaphylatoxin C3a stimulation of mast cells
- PMID: 1373170
A mechanism of action for anaphylatoxin C3a stimulation of mast cells
Abstract
Incubation of either C3a, C3ades Arg, or synthetic analogues of the C-terminal sequence of C3a with purified rat peritoneal mast cells resulted in a rapid and dose-dependent histamine release. The natural factors C3a and C3ades Arg were the most active of the factors tested exhibiting EC50 values of 3.3 and 2.2 microM, respectively. The corresponding 21- and 22-residue C-terminal analogues of C3a (Y21R and Y21) were less potent than intact factor exhibiting EC50 values of 10.9 and 25.1 microM, respectively. Histamine was released in a nonlytic manner and the mast cell stimulation by both natural and synthetic factors was sensitive to pertussis toxin, neuraminidase, benzalkonium chloride, and to an excess of calcium. C3a stimulated the generation of inositol polyphosphates that was inhibited by either pertussis toxin or benzalkonium chloride. The C3a anaphylatoxin also directly stimulates purified G proteins (i.e., GTPase activity) in a dose-dependent manner. The evident correlation between efficiency of C3a and C3a analogues to stimulate purified G proteins and their capacity to induce cellular histamine release led us to conclude that C3a fails to activate mast cells via a mechanism involving specific receptors on the cell. Instead, we propose that C3a either causes direct activation of G proteins of the Gi subtype, with a subsequent activation of phospholipase C, or interacts with a binding site of the cell surface specific for cationic molecules that is coupled to the G protein cascade.
Similar articles
-
Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells.Mol Pharmacol. 1990 Dec;38(6):816-22. Mol Pharmacol. 1990. PMID: 1701214
-
Activation of rat peritoneal mast cells by substance P and mastoparan.J Pharmacol Exp Ther. 1989 Jul;250(1):329-35. J Pharmacol Exp Ther. 1989. PMID: 2473189
-
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway.J Immunol. 1996 Aug 15;157(4):1693-8. J Immunol. 1996. PMID: 8759757
-
Peptidergic pathway in human skin and rat peritoneal mast cell activation.Immunopharmacology. 1994 Jan-Feb;27(1):1-11. doi: 10.1016/0162-3109(94)90002-7. Immunopharmacology. 1994. PMID: 7515863 Review.
-
G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides.Trends Pharmacol Sci. 1990 Sep;11(9):358-62. doi: 10.1016/0165-6147(90)90179-c. Trends Pharmacol Sci. 1990. PMID: 2122563 Review.
Cited by
-
Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases.Heliyon. 2022 Jun 4;8(6):e09575. doi: 10.1016/j.heliyon.2022.e09575. eCollection 2022 Jun. Heliyon. 2022. PMID: 35706935 Free PMC article. Review.
-
Nonsense-codon-mediated decay in human hereditary complement C3 deficiency.Immunogenetics. 2004 Jan;55(10):667-73. doi: 10.1007/s00251-003-0624-3. Epub 2003 Nov 25. Immunogenetics. 2004. PMID: 14639503
-
Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages.Immunology. 1993 Aug;79(4):633-8. Immunology. 1993. PMID: 8406589 Free PMC article.
-
G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2.Eur J Pharmacol. 2011 Oct 1;668(1-2):299-304. doi: 10.1016/j.ejphar.2011.06.027. Epub 2011 Jul 3. Eur J Pharmacol. 2011. PMID: 21741965 Free PMC article.
-
Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease.Clin Exp Immunol. 2000 Apr;120(1):30-7. doi: 10.1046/j.1365-2249.2000.01168.x. Clin Exp Immunol. 2000. PMID: 10759760 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources